Keywords
Signs and Symptoms
Gastrointestinal tract
How to Cite
Copyright © | All rights reserved.
The journal holds the exclusive copyright for the publication of this article under the terms of Brazilian law 9610/98.
Partial reproduction
The use of parts of the texts, figures and questionnaire of the article is free, being mandatory the citation of the authors and journal.
Total reproduction
It is expressly prohibited and must be authorized by the journal.
Abstract
Objective: To identify the gastrointestinal clinical manifestations prevalent in patients with COVID-19 in a hospital in Goiás, in the year 2021. Methods: This is an observational study, conducted with data collection from 153 medical records, carried out at a hospital in Goiás. The presence of gastrointestinal symptoms at admission and during evolution were investigated, in addition to gender, age, previous comorbidities, liver and canalicular markers, and clinical outcome. The data obtained were analyzed by descriptive statistics with the aid of the BI software. The study was approved by the Research Ethics Committee. Results: Most of the sample was between 40 and 59 years old (41.8%), male (50.3%) and had some previous comorbidity, the most common being arterial hypertension systemic (41.1%). A high prevalence of gastrointestinal symptoms was found, present in most of the patients evaluated (18.3%). The most common symptoms at admission were inappetence (66%), nausea (22.6%) and diarrhea (18.9%), and the most common symptoms during evolution were constipation (63.1%), inappetence (38, 1%) and diarrhea (17.1%). Conclusion: It is concluded that most patients with COVID-19 presented gastrointestinal symptoms at some point.
References
BRITO APSO, et al. Manifestações gastrointestinais em pacientes infectados pelo SARS-CoV-2: Revisão sistemática da literatura. Brazilian Journal of Health Review, 2020; 3(5):14570-14583.
CAI Q, et al. COVID-19: Abnormal liver function tests. Journal of hepatology, 2020; 73(3): 566-574.
CUICCHI D, et al. Fecal-oral transmission of SARS-CoV-2: review of laboratory-confirmed virus in gastrointestinal system. International journal of colorectal disease, 2020; 36: 437-444.
DHAR D, MOHANTY A. Gut microbiota and COVID-19 - possible link and implications. Virus research, 2020, 285: 1-6.
DING S, LIANG TJ. Is SARS-CoV-2 also an enteric pathogen with potential for fecal-oral transmission? A COVID-19 clinical and virological review. Elsevier Public Health Emergency Collection: Gastroenterology, 2020; 159 (1): 53-61.
GOYAL H, et al. Clinical insights into the gastrointestinal manifestations of COVID-19. Nature Public Health Emergency Collection, 2020; 65(1): 1932-1939.
HUNG YP, et al. Gut Dysbiosis during COVID-19 and Potential Effect of Probiotics. Microrganisms, 2021; 9(8): 1605-1616.
KAAFARANI HMA, et al. Gastrointestinal Complications in Critically Ill Patients With COVID-19. Annals of surgery, 2020; 272(2): 61-62.
KHAN MU, et al. Digestive system involvement and clinical outcomes among COVID-19 patients: A retrospective cohort study from Qatar. World J Gastroenterol, 2021; 27(46): 7995-8009.
KOPEL J, et al. Clinical Insights into the Gastrointestinal Manifestations of COVID-19. Nature Public Health Emergency Collection, 2020; 23: 1-8.
KRISHNAN A, et al. Abnormal liver chemistries as a predictor of COVID-19 severity and clinical outcomes in hospitalized patients. World J Gastroenterol, 2022; 28(5): 570-587.
LEI F, et al. Longitudinal Association Between Markers of Liver Injury and Mortality in COVID-19 in China. Hepatology, 2020; 72(2): 389-398.
MARQUES RDC, et al. A pandemia de COVID-19: Interseções e desafio para a história da saúde e do tempo presente. Coleção História do Tempo Presente, 2020; 3: 225-249.
MONTAZERI M, et al. Clinical characteristics of COVID-19 patients with gastrointestinal symptoms. Arch Iran Med, 2021; 24(2): 131-136.
MORAIS LRD, et al. COVID-19 e o trato gastrointestinal: fisiopatologia e evolução clínica dos pacientes. Brazilian Journal of Health Review, 2021, 4(2): 4556-4569, 2021.
OGASSAWARA, MY, et al. Sintomas gastrointestinais em pacientes com COVID-19: relação com a gravidade e complicações da doença, Revista Eletrônica Acervo Saúde, 2021; 27: e7817.
PENNINGER JM, et al. The Role of Angiotensin Converting Enzyme 2 in Modulating Gut Microbiota, Intestinal Inflammation, and Coronavirus Infection. Gastroenterology, 2020; 160(1): 39-46.
RAMACHANDRAN P, et al. Gastrointestinal Symptoms and Outcomes in Hospitalized Coronavirus Disease 2019 Patients. Dig Dis, 2020; 38(5): 373-379.
RIOS DL, et al. Probióticos: como uma microbiota intestinal saudável ajuda a combater infecções respiratórias virais agudas, similares à covid-19. Revista Eletrônica Acervo Saúde, 2020; 46: e3537.
TABARY M, et al. Pathologic features of COVID-19: A concise review. Pathology-Research and Practice, 2020, 216(9): 1-5.
SUN Y, et al. Gastrointestinal and hepatic injury associated with COVID-19: clinical characteristics and potential mechanisms. Signal Transduction and Targeted Therapy, 2020; 256 (5): 1-8.
XAVIER-SANTOS D, et al. Evidences and perspectives of the use of probiotics, prebiotics, synbiotics, and postbiotics as adjuvants for prevention and treatment of COVID-19: A bibliometric analysis and systematic review. Trends in Food Science & Technology, 2022; 120: 174-192.
YE Q, et al. The mechanism and treatment of gastrointestinal symptoms in patients with COVID-19. Am J Physiol Gastrointest Liver Physiol, 2020, 319(2): G245-G252.
ZHANG F, et al. Gut microbiota in COVID-19: key microbial changes, potential mechanisms and clinical applications. Nature Reviews Gastroenterology & Hepatology, 2023, 20(5): 323-337
ZHONG P, et al. COVID-19-associated gastrointestinal and liver injury: clinical features and potential mechanisms. Signal Transduction and Targeted Therapy, 2020, 5(1): 1-8.